High Quality CAS 59-05-2 Methotrexate Inhibitors Bases Methotrexate

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Methotrexate
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Methotrexate
• Name: Methotrexate Powder
• Appearance: Yellow Powder
• Colour: Yellow
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Density: 1.536
• CAS: 59-05-2
• Mf: C20h22n8o5
• MW: 454.43928
• Melting Point: 195c
• Boiling Point: 561.26 ° C (Rough Estimate)
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Methotrexate
• Origin: Xian
• Production Capacity: 1000kg/Month

Product Description

High Quality CAS 59-05-2 Methotrexate Inhibitors Bases Methotrexate

Product Description

Product Details

Product Name	Methotrexate
Appearance	Methotrexate Powder
Assay	>99%
MW	454.43928
MF	C20H22N8O5
Melting point	195C
Boiling point	561.26C (rough estimate)

The corresponding compound of CAS 59-05-2 is methotrexate, which is an antineoplastic drug of folic acid antagonist. It blocks DNA synthesis by competitively inhibiting dihydrofolate reductase, thereby inhibiting tumor cell proliferation. It is clinically used to treat acute lymphocytic leukemia, breast cancer, choriocarcinoma and other malignant tumors. Simultaneously possessing immunosuppressive effects, it is used for autoimmune diseases such as rheumatoid arthritis and psoriasis by inhibiting interleukin-2 synthesis and neutrophil chemotaxis. When used in large doses, it is necessary to use calcium folinate to detoxify and reduce liver toxicity. Storage should be kept away from light and sealed in a dry environment at 4 ºC. In 2017, it was classified as a Group 3 carcinogen by the World Health Organization.

Application&Function

Methotrexate is a folate antagonist class of antimetabolites, appearing as yellow crystalline powder or white solid.

Main pharmacological effects and uses

Antitumor and immune suppression
It blocks DNA synthesis by competitively inhibiting dihydrofolate reductase (DHFR), and is used to treat acute leukemia, lymphoma, breast cancer and other malignant tumors.
As an immunosuppressant, it is used for autoimmune diseases such as rheumatoid arthritis and psoriasis.

Target and efficacy
Common dosage forms include injections and tablets, which should be stored in a dry environment at -20 ° C or 4 ° C away from light.
precautions
Poor water solubility (insoluble in H2O), attention should be paid to the administration method.
Clinical monitoring of liver and kidney function, as well as adverse reactions such as bone marrow suppression, is necessary.

This drug has dual effects of anti-tumor and immune regulation, and is a core therapeutic drug for various malignant diseases and chronic inflammation.

Specification